SEC Tracker
Get the app
COGT · XBRL financial data

Cogent Biosciences financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (COGT's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Research and development5049*53546462*63626976*7571
General and administrative910*10101212*12131424*2832
Operating income (loss)(60)(58)*(62)(64)(75)(74)*(75)(76)(83)(99)*(104)(103)
Interest income44*4554*3245*87
Interest expense———————011*11
Other income (expense)0(0)*(0)002*(0)(0)(0)(0)*(0)(0)
Income tax expense (benefit)—————————year only——
Net income (loss)(55)(54)*(58)(59)(71)(68)*(72)(74)(81)(102)*(97)(96)
Earnings per share, basic USD per share(0.64)(0.63)*(0.62)(0.59)(0.64)—(0.52)(0.53)(0.50)(0.68)*(0.53)(0.52)
Earnings per share, diluted USD per share(0.64)(0.63)*(0.62)(0.59)(0.64)—(0.52)(0.53)(0.50)(0.68)*(0.53)(0.52)
Weighted average shares, basic millions of shares8687*9599110111*113114138150*162171
Weighted average shares, diluted millions of shares8687*9599110111*113114138150*162171

Balance sheet

CSV

Fiscal quarters (COGT's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents8753216889798126128125312241181
Marketable securities192212220275238189120110266589625611
Marketable securities, non-current34702710———————
Prepaid and other current assets756769776101113
Total current assets286271442370342296253245397910878805
Property and equipment, net988776665555
Right-of-use asset222222212120201919181823
Total assets355313476430384328284275426938903835
Accounts payable1011169151214171610147
Total current liabilities353837405356495862645859
Long-term debt—————0—4444———
Lease liability, non-current181717171616151515141419
Total liabilities53565457697265120123301295302
Accumulated deficit(549)(604)(662)(721)(792)(859)(931)(1,005)(1,086)(1,188)(1,286)(1,382)
Total stockholders' equity303258422373315256219155302636608532
Total liabilities and equity355313476430384328284275426938903835
Common shares outstanding (cover page) millions of shares8610496109110114114140142162171174

Cash flows

CSV

Fiscal quarters (COGT's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(55)(54)*(58)(59)(71)(68)*(72)(74)(81)(102)*(97)(96)
Stock-based compensation9*9*910*10*10*1010*11*16*1717*
Net cash from operating activities(38)*(44)*(53)(43)*(52)*(61)*(67)(55)*(64)*(79)*(87)(77)*
Purchases of property and equipment0*0*00*0*0*10*0*1*00*
Net cash from investing activities(91)*10*1(85)*60*62*699*(155)*(323)*(36)14*
Proceeds from issuing common stock(0)*0*——0*0*——————
Proceeds from long-term debt—year only———year only——0*0*——
Net cash from financing activities1*0*214(0)*1*0*2547*217*589*533*
Net change in cash(128)*(34)*163(128)*9*1*282*(2)*187*(71)(60)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Cogent Biosciences181not reported(77)*173.5M10.3 quarters 10-QJun 30, 2026
uniQure985.2(48)*70.1M2.6 quarters 10-QSep 30, 2026
Phibro Animal Health61397*24*not reported— 10-KJun 30, 2026
Pacira BioSciences20619257*39.9M— 10-QJun 30, 2026
Syndax Pharmaceuticals13683(27)*not reported11.9 quarters 10-QSep 30, 2026
Nurix Therapeutics720673616*109.2M— 10-QAug 31, 2026
Niagen Bioscience67302.8*79.1M— 10-QJun 30, 2026
Immunome2180(62)*113.6M8.4 quarters 10-QJun 30, 2026
Anavex Life Sciences118not reported(9.1)*92.7M13.0 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.